- Home
- LENZ vs SLRC Comparison
LENZ vs SLRC Comparison
Compare LENZ & SLRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LENZ
- SLRC
- Stock Information
- Founded
- LENZ 2019
- SLRC 2007
- Country
- LENZ United States
- SLRC United States
- Employees
- LENZ N/A
- SLRC N/A
- Industry
- LENZ Medicinal Chemicals and Botanical Products
- SLRC Finance/Investors Services
- Sector
- LENZ Health Care
- SLRC Finance
- Exchange
- LENZ Nasdaq
- SLRC Nasdaq
- Market Cap
- LENZ 819.1M
- SLRC 889.2M
- IPO Year
- LENZ 2021
- SLRC 2010
- Fundamental
- Price
- LENZ $29.12
- SLRC $16.69
- Analyst Decision
- LENZ Strong Buy
- SLRC Hold
- Analyst Count
- LENZ 5
- SLRC 6
- Target Price
- LENZ $41.80
- SLRC $15.79
- AVG Volume (30 Days)
- LENZ 180.2K
- SLRC 137.9K
- Earning Date
- LENZ 05-07-2025
- SLRC 05-07-2025
- Dividend Yield
- LENZ N/A
- SLRC 9.79%
- EPS Growth
- LENZ N/A
- SLRC N/A
- EPS
- LENZ N/A
- SLRC 1.61
- Revenue
- LENZ N/A
- SLRC $227,510,000.00
- Revenue This Year
- LENZ N/A
- SLRC N/A
- Revenue Next Year
- LENZ $534.98
- SLRC N/A
- P/E Ratio
- LENZ N/A
- SLRC $10.41
- Revenue Growth
- LENZ N/A
- SLRC N/A
- 52 Week Low
- LENZ $14.42
- SLRC $13.64
- 52 Week High
- LENZ $38.93
- SLRC $17.94
- Technical
- Relative Strength Index (RSI)
- LENZ 58.64
- SLRC 59.19
- Support Level
- LENZ $28.51
- SLRC $16.21
- Resistance Level
- LENZ $30.09
- SLRC $16.83
- Average True Range (ATR)
- LENZ 1.44
- SLRC 0.22
- MACD
- LENZ 0.03
- SLRC 0.04
- Stochastic Oscillator
- LENZ 85.43
- SLRC 73.85
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
About SLRC SLR Investment Corp.
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.